Intranasal drug delivery device market seen reaching $99.11 billion by 2030

The Business Research Company says the intranasal drug delivery devices market will grow from $65.09 billion in 2025 to $70.77 billion in 2026, then climb to $99.11 billion by 2030. Rising chronic disease rates, demand for non-invasive treatment and expansion in homecare use are among the main growth drivers.

Why it matters: - Intranasal drug delivery devices are gaining importance because they offer a non-invasive way to deliver medicine quickly through the nasal cavity. - The market outlook points to sustained double-digit-scale growth in dollars, with demand tied to respiratory, neurological and chronic disease treatment. - The shift toward homecare and self-administration could reshape how some therapies are delivered outside traditional clinical settings.

What happened: - The Business Research Company published a report titled Intranasal Drug Delivery Devices Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report estimates the market will rise from $65.09 billion in 2025 to $70.77 billion in 2026. - The forecast says the market will reach $99.11 billion by 2030. - North America held the largest market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available through the company's sample page. - The full report is available through the company's report page.

The details: - The report lists a 2026 to 2030 compound annual growth rate of 8.8%. - The earlier market growth was linked to more respiratory and nasal disorders, greater use of nasal routes for systemic drug delivery, growth in self-administration devices, approvals of new intranasal therapies and more outpatient treatment models. - The forecast is supported by growth in biologics and vaccine development via nasal delivery. - The report also points to stronger demand for homecare drug administration. - Expanded use in neurological treatments is another expected growth driver. - Investment in drug-device combinations is increasing. - Patient adherence solutions are becoming a bigger focus. - The report highlights precision nasal delivery systems, multi-dose devices, patient-friendly delivery formats and faster absorption as emerging trends. - Intranasal drug delivery devices include sprays, powders and liquid solutions. - These devices are designed to deliver medication directly into the nasal cavity, where the surface area and blood supply support rapid absorption. - The report says the market is being helped by rising chronic disease rates. - In June 2024, the UK National Health Service reported 3,615,330 people at risk for type 2 diabetes in England in 2023, up from 3,066,330 in 2022. - The same NHS data showed 549,000 more people identified with pre-diabetes conditions such as non-diabetic hyperglycemia.

Between the lines: - The market forecast suggests intranasal delivery is moving beyond niche use and into broader drug-development planning. - The emphasis on biologics and vaccines signals that nasal delivery is being viewed as a route for more complex therapies, not just routine medication formats. - North America's lead suggests the region remains a key early adopter for new drug-device combinations and commercial launches.

What's next: - The report expects continued adoption of non-invasive administration formats through 2030. - Future growth will likely track progress in biologics, neurological therapies and home-use delivery systems. - Device makers will probably keep pushing toward multi-dose, patient-friendly and rapid-absorption formats.

The bottom line: - Intranasal drug delivery devices are on a strong growth path, with the market projected to add more than $34 billion between 2025 and 2030.